Mumbai, Aug. 12 -- Under the agreement, Sandoz will handle commercialization of the biosimilar across the European Union (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia. Lupin will be responsible for manufacturing the product and managing regulatory submissions. In most designated markets, Sandoz will have exclusive marketing rights, while in France, Australia, Vietnam, and Malaysia, the rights will be semi-exclusive.

Additionally, through a separate agreement, Sandoz will acquire sole commercialization rights for Lupin's biosimilar ranibizumab in Canada, with Lupin continuing to manage manufacturing and regulatory filings.

Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment tha...